Trials / Not Yet Recruiting
Not Yet RecruitingNCT07256756
A Study of GC203 TIL in Advanced Solid Tumors (NF)
A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Shanghai Juncell Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC203 TIL | A tumor sample is resected from each participant and cultured ex vivo to expand the population of engineered tumor infiltrating lymphocytes injection (GC203 TIL). After lymphodepletion, patients are infused GC203 TIL. |
Timeline
- Start date
- 2026-01-30
- Primary completion
- 2026-11-30
- Completion
- 2028-11-30
- First posted
- 2025-12-01
- Last updated
- 2025-12-23
Source: ClinicalTrials.gov record NCT07256756. Inclusion in this directory is not an endorsement.